ArticleAntimicrobial agents and chemotherapy2012
PD 404,182 is a virocidal small molecule that disrupts hepatitis C virus and human immunodeficiency virus.
Article in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 38 citations in OpenAlex.
- PA-824 inhibits porcine epidemic diarrhea virus infectionJournal of virology · 2024Article
- Axenic Long-Term Cultivation ofJournal of fungi (Basel, Switzerland) · 2023Article
- Synthesis of imidazo[4,5-Beilstein journal of organic chemistry · 2023Article
- High-Throughput In Vitro Screening Identified Nemadipine as a Novel Suppressor of Embryo Implantation.International journal of molecular sciences · 2022Article
- Identification of 3,4-Dihydro-2International journal of molecular sciences · 2021Article
- High-Throughput Screening for Inhibitors of the SARS-CoV-2 Protease Using a FRET-Biosensor.Molecules (Basel, Switzerland) · 2020Article
- CuI nanoparticle-catalyzed synthesis of tetracyclic benzo[RSC advances · 2018Article
- Inhibitors of the Hydrolytic Enzyme Dimethylarginine Dimethylaminohydrolase (DDAH): Discovery, Synthesis and Development.Molecules (Basel, Switzerland) · 2016Review
- A p7 Ion Channel-derived Peptide Inhibits Hepatitis C Virus Infection in Vitro.The Journal of biological chemistry · 2015Article
- Herpes simplex virus 2 infection: molecular association with HIV and novel microbicides to prevent disease.Medical microbiology and immunology · 2015Review
- Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide.Antimicrobial agents and chemotherapy · 2014Article
- A novel and potent inhibitor of dimethylarginine dimethylaminohydrolase: a modulator of cardiovascular nitric oxide.The Journal of pharmacology and experimental therapeutics · 2014Article
- Liposomes as nanocarriers for anti-HIV therapy.Drug delivery and translational research · 2013Article
- Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes.Antimicrobial agents and chemotherapy · 2013Article
- 5-(Perylen-3-yl)ethynyl-arabino-uridine (aUY11), an arabino-based rigid amphipathic fusion inhibitor, targets virion envelope lipids to inhibit fusion of influenza virus, hepatitis C virus, and other enveloped viruses.Journal of virology · 2013Article
- A screen for genetic suppressor elements of hepatitis C virus identifies a supercharged protein inhibitor of viral replication.PloS one · 2013Article
- Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells.PloS one · 2013Article
- Development of novel entry inhibitors targeting emerging viruses.Expert review of anti-infective therapy · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
We describe a virucidal small molecule, PD 404,182, that is effective against hepatitis C virus (HCV) and human immunodeficiency virus (HIV). The median 50% inhibitory concentrations (IC(50)s) for the antiviral effect of PD 404,182 against HCV and HIV in cell culture are 11 and 1 μM, respectively. The antiviral activity of PD 404,182 is due to the physical disruption of virions that is accompanied to various degrees (depending on the virus and exposure temperature/time) by the release of viral nucleic acids into the surrounding medium. PD 404,182 does not directly lyse liposomal membranes even after extended exposure, and it shows no attenuation in antiviral activity when preincubated with liposomes of various lipid compositions, suggesting that the compound inactivates viruses through interaction with a nonlipid structural component of the virus. The virucidal activity of PD 404,182 appears to be virus specific, as little to no viral inactivation was detected with the enveloped Dengue and Sindbis viruses. PD 404,182 effectively inactivates a broad range of primary isolates of HIV-1 as well as HIV-2 and simian immunodeficiency virus (SIV), and it does not exhibit significant cytotoxicity with multiple human cell lines in vitro (50% cytotoxic concentration, >300 μM). The compound is fully active in cervical fluids, although it exhibits decreased potency in the presence of human serum, retains its full antiviral potency for 8 h when in contact with cells, and is effective against both cell-free and cell-associated HIV. These qualities make PD 404,182 an attractive candidate anti-HIV microbicide for the prevention of HIV transmission through sexual intercourse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.